Crucial Fact

  • Her favourite word was fact.

Last in Parliament November 2005, as Liberal MP for Edmonton Centre (Alberta)

Lost her last election, in 2006, with 39% of the vote.

Statements in the House

Government Contracts March 17th, 2003

Mr. Speaker, as I mentioned earlier, Health Canada officials are reviewing this matter and they will be informing me of the outcome of their review in the days ahead.

At this point it would be inappropriate for me to say anything further other than to confirm that the person in question is no longer employed by the Department of Health.

Government Contracts March 17th, 2003

Mr. Speaker, let me clarify that the person named Joanne Meyer no longer works in the Department of Health. In fact, her relationship with the department ended in January 2002. It is my understanding that health officials are reviewing at this time contractual arrangements and they will let me know what their review highlights in the coming weeks.

Question No. 105 February 28th, 2003

The answer is as follows:

(a) Breast cancer continues to be the most frequently diagnosed cancer for women. One in nine women are expected to develop breast cancer and one in twenty-seven are expected to die of the disease. Following small but steady annual increases over three decades, breast cancer incidence among women levelled off in 1993. Mortality rates for breast cancer have declined steadily since 1986. This pattern of divergent trends is consistent with the benefits being achieved through screening programs and improved treatments.

The table below indicates the incidence and mortality* rates for breast cancer, female only, in Canada for the years 1990 to 1999.

  • Age-standardized rate: The number of new cases of cancer or cancer deaths per 100,000 that would have occurred in the standard population, 1991 Canadian population, if the actual age-specific rates observed in a given population had prevailed in the standard population.

(b) Prostate cancer will continue to be the most frequently occurring cancer for Canadian men. One in eight men will develop prostate cancer during their lifetime, mostly after age 70 and one in twenty-eight will die of the disease. Beginning in 1994, incidence rates* for prostate cancer began to decline after having increased rapidly for several years. Mortality rates for prostate cancer peaked between 1991 and 1995 and have fallen since. Increases in prostate cancer incidence in the early 1990's were likely due to the rapid increase in the use of early detection techniques.

The table below indicates the incidence and mortality* rates for prostate cancer in Canadian men for the years 1990 to 1999.

  • Age-standardized rate: The number of new cases of cancer or cancer deaths per 100,000 that would have occurred in the standard population, 1991 Canadian population, if the actual age-specific rates observed in a given population had prevailed in the standard population.

(c) The table below describes the Federal contributions towards breast cancer research. Partners include the Canadian Institutes for Health Research, CIHR, and Health Canada, HC.

(d) Federal tax dollars contributed towards prostate cancer research is as follows:

(e) Mammograms are paid for by publicly funded health care insurance in all provinces and territories when used as a tool in the early detection of breast cancer.

(f) Currently, Saskatchewan is the only province in which prostate specific antigen, PSA, tests are paid for by publicly funded health care insurance when used for screening asymptomatic men. However, prostate specific antigen tests are paid for by publicly funded health care insurance in all provinces and territories when used for diagnostic and monitoring purposes.

Due to a lack of evidence that PSA screening reduces death from prostate cancer, it is not a proven tool in the early detection of prostate cancer. The Canadian Task Force on Preventive Health Care recommends against the use of PSA test for routine screening purposes.

Health February 26th, 2003

Mr. Speaker, it is most unfortunate that the hon. member chooses to misconstrue and misrepresent the comments that I made, but he does raise a serious point. That is in relation to both the cost and utilization of drugs in the Canadian health care system.

If the hon. member had taken the time to read the recent health accord, he would have seen that the first ministers have instructed their health ministers to take up both issues, the overall cost of drugs in our health care system and also the equally important issue of utilization, how drugs are used and are we getting better health outcomes for all Canadians in the use of those drugs.

Health February 21st, 2003

Mr. Speaker, this is a very important issue that my colleague raises, so let me take him through the situation that presently exists. Health Canada has worked for some time with the Canadian Standards Association, provinces and other stakeholders to set standards aimed at ensuring the safety of cells, tissues and organs for transplantation.

In January, Health Canada issued a directive communicating these standards to establishments across Canada. Next March, these standards will have the force of law as regulations. In the meantime, Health Canada will exercise its authority under the Food and Drugs Act to prohibit distribution of such products where evidence shows that they are not--

Motions for Papers February 19th, 2003

Mr. Speaker, I ask that Motion No. P-27 be transferred for debate.

Health February 18th, 2003

Mr. Speaker, we are looking at all aspects of our drug approval process. We are looking at the time it takes. We are comparing those approval times with other countries' standards. We are working with the private sector, including drug companies.

We take this very seriously, which is why in fact this was an important commitment made in the Speech from the Throne.

Health February 18th, 2003

Mr. Speaker, I am very pleased that hon. member has raised this question, because I am sure he read the Speech from the Throne, where in fact the government made a very important commitment in relation to smart regulation.

In fact, we understand the challenge in relation to drug approval times. We are reviewing and in fact are in consultations now to determine how we can put in place a renewed drug approval process that meets the needs of all Canadians.

Health February 17th, 2003

Mr. Speaker, I have no doubt that the Prime Minister will listen intently to the views of the three territorial leaders who are, in fact, with us this afternoon.

In fact, as has often been referenced in the House, we on the government side are all aware of the unique health challenges that are faced by those who live in the north. I look forward to the meeting that the Prime Minister will have with the three territorial leaders because I know working together--

Health February 12th, 2003

Mr. Speaker, what I said yesterday was that I am going to sit down with my territorial health colleagues on Monday, February 24, and I am going to listen to them about the challenges they face and will face in implementing the health accord agreed to by first ministers last week.

Certainly I am aware of the unique challenges that my northern colleagues face. I hope to be able to work collaboratively with them to ensure that they secure the benefits for their people which we know will flow from our renewed commitment to health care in this country.